user

Real-world effectiveness of MD1003 (high dose pharmaceutical grade biotin) in patients with progressive MS

被引：0
|
作者：
Faure, J.
Jauffret, J.
Carreau, C. [1 ,2 ]
Legrain, P. [1 ,2 ]
Castex, C. [1 ]
Tourbah, A.
机构：
[1] CHU Reims, Reims, France
[2] Univ Reims, Reims, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P585
引用
下载
收藏
页码：281 / 282
页数：2
相关论文
共 50 条
  • [21] Effect of MD1003 (High-Dose Pharmaceutical Biotin) in Spinal Progressive Multiple Sclerosis (MS-SPI): EDSS Sub-Scores
    Papeix, Caroline
    Lebrun-Frenay, Christine
    Defer, Gilles
    Laubage, Pierre
    Ruiz, Marta
    Simon, Olivier
    Sedel, Frederic
    Tourbah, Ayman
    Lasser, Robert
    Morteau, Olivier
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 34 - 34
  • [22] Effect of MD1003 (high dose pharmaceutical grade biotin) on dexterity, cognitive, and quality of life measures in a cohort of patients with non-active progressive multiple sclerosis
    Donze, C.
    Guyot, M. A.
    Lenne, B.
    Massot, C.
    Kwiatkowski, A.
    Hautecoeur, P.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 915 - 915
  • [23] High Dose Pharmaceutical Grade Biotin (MD1003) Accelerates Differentiation of Murine and Grafted Human Oligodendrocyte Progenitor Cells In Vivo
    Levy, Marion J. F.
    Garcia-Diaz, Beatriz
    Sedel, Frederic
    Baron-Van Evercooren, Anne
    Mozafari, Sabah
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (24)
  • [24] Effects of high dose pharmaceutical grade biotin (MD1003), on survival, ensheathment, and ATP production by oligodendrocyte lineage cells in vitro
    Cui, Q. -L.
    Lin, Y. H.
    Xu, Y. K. T.
    Rao, V. T.
    Perdomini, M.
    Bernard, D.
    Antel, J.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 676 - 676
  • [25] High Dose Pharmaceutical Grade Biotin (MD1003) Accelerates Differentiation of Murine and Grafted Human Oligodendrocyte Progenitor Cells In Vivo
    Mozafari, S.
    Levy, M. J. F.
    Garcia-Diaz, B.
    Sedel, F.
    Van Evecooren, A. Baron
    GLIA, 2023, 71 : E743 - E743
  • [26] Effect of MD1003 (High-Dose Biotin) in spinal progressive multiple sclerosis (MS-SPI): subgroup analyses
    Laplaud, D. -A.
    Gout, O.
    Clavelou, P.
    Pelletier, J.
    Sedel, F.
    Tourbah, A.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 402 - 403
  • [27] Effect of MD1003 (high dose pharmaceutical grade biotin) on remotely monitored ambulatory activity in progressive MS: initial step count data of the phase 3 SPI2 study
    Block, V.
    Gelfand, J.
    Sedel, F.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 569 - 570
  • [28] Effect of MD1003 (High-Dose Biotin) for the treatment of progressive MS: 36-month follow-up data
    Vukusic, S.
    De Seze, J.
    Edan, G.
    Moreau, T.
    Brochet, B.
    Lasser, R.
    Tourbah, A.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 401 - 402
  • [29] MD1003 (High-Dose Pharmaceutical Biotin) for the Treatment of Progressive Multiple Sclerosis: Baseline Data and Results from an Early Access Program
    Brassat, David
    Hautecoeur, Patrick
    Durand-Dubief, Francoise
    Castelnovo, Giovanni
    Derache, Nathalie
    Bourre, Bertrand
    Donze, Cecile
    Ouallet, Jean-Christophe
    Collongues, Nicolas
    Simon, Olivier
    Brion, Guillaume
    Sedel, Frederic
    Vermersch, Patrick
    Lasser, Robert
    Morteau, Olivier
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 31 - 32
  • [30] MD1003 (high doses of biotin) in progressive multiple sclerosis: subgroup analyses of the MS-SPI trial
    Tourbah, A.
    Lebrun-Frenay, C.
    Edan, G.
    Clanet, M.
    Papex, C.
    Vukusic, S.
    De Sesze, J.
    Debouverie, M.
    Gout, O.
    Clavelou, P.
    Defer, G.
    Laplaud, D.
    Moreau, T.
    Labauge, P.
    Brochet, B.
    Sedel, F.
    Pelletier, J.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 785 - 785
12345